Showing results (1-10 of 149) with videos related to
Sort By:
Pageof 15
Revue Neurologique|December 3, 1998
Exploratory studies: implications for drug development in Alzheimer's diseaseN R Cutler, J J SramekExpert Opinion on Investigational Drugs|November 4, 2000
Ongoing trials in Alzheimer's diseaseJ J Sramek, N R CutlerAlzheimer Disease and Associated Disorders|February 24, 2001
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?J J Sramek, N R CutlerProgress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug developmentN R Cutler, J J SramekAlzheimer Disease and Associated Disorders|January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"N R Cutler, J J SramekDrugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R CutlerAlzheimer Disease and Associated Disorders|July 3, 1998
Guidelines for conducting bridging studies in Alzheimer diseaseN R Cutler, J J SramekEuropean Journal of Clinical Pharmacology|January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging studyN R Cutler, J J SramekExpert Opinion on Investigational Drugs|April 3, 2001
The status of ongoing trials for mild cognitive impairmentJ J Sramek, A E Veroff, N R CutlerProgress in Neuro-Psychopharmacology & Biological Psychiatry|May 1, 1994
A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorderN R Cutler, J M Hesselink, J J SramekPageof 15